139:(FRM) (1999), Mergier-Bourdeix Prize from the French Academy of sciences (2004), Griffuel Prize from the Association de recherche en Cancérologie (ARC) (2010), Claude Bernard Prize of the City of Paris (2010), the Chinese Office Science and Technology International Cooperation Prize (2011), the Ernest Beutler Award of the
119:. In vivo modelling of the disease allowed him to discover that the combination of retinoic acid and arsenic is capable of eradicating the disease. These models found clinical application in treatments that can cure the vast majority of patients without the use of genotoxic
103:
research unit, then CNRS/Inserm/University (molecular pathology) from 1995 to 2018. He is, or has been, a member of numerous evaluation and advisory structures in France and abroad. He is a member of the editorial boards of Cancer
Research, then Cancer Discovery.
332:
Lallemand-Breitenbach, V., M.-C. Guillemin, A. Janin, M.-T. Daniel, L. Degos, S.C. Kogan, J.M. Bishop, and H. de The, « Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia »,
259:
Chomienne, C., P. Ballerini, M. Balitrand, M. Huang, I. Krawice, S. Castaigne, P. Fenaux, P. Tiollais, A. Dejean, L. Degos, and H. de Thé, « The retinoic acid receptor is rearranged in retinoic acid sensitive promyelocytic leukemias »,
277:
de Thé, H., C. Lavau, A. Marchio, C. Chomienne, L. Degos, and A. Dejean, « The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR »,
241:
de The, H., C. Chomienne, M. Lanotte, L. Degos, and A. Dejean, « The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus »,
389:
54:
Thé's father was a doctor and biologist. He spent the first years of his life in the United States. After a period in preparatory classes, he studied medicine and biological sciences in parallel, first in
111:
control or nuclear organization in the pathogenesis of this disease. In particular, he will seek to understand the molecular and cellular bases of PML/RARA targeting by retinoic acid and later by
224:
de Thé, H., M.d.M. Vivanco-Ruiz, P. Tiollais, H. Stunnenberg, and A. Dejean, « Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene »,
123:. In addition to their medical applications, his work has opened up new perspectives in very fundamental biological fields, such as nuclear organization or protein stability control.
207:
de The, H., A. Marchio, P. Tiollais, and A. Dejean, « A novel steroid thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma »,
409:
107:
His work, directly inspired by clinical observations and carried out in collaboration with French and
Chinese teams, lead to new insights into the roles of differentiation,
399:
68:
100:
79:
signalling, in particular with the cloning of RARB and the identification of the first element of response to this hormone. Together with
Laurent Degos and
87:
to retinoic acid, which lead him to identify the reworking of the RARA gene in this disease and describe the PML/RARA fusion. Recruited as a researcher at
148:
136:
194:
132:
115:. His team showed that retinoic acid and arsenic are targeted treatments that bind directly to PML/RARA and induce its degradation by the
144:
60:
315:
de The, H., P.P. Pandolfi, and Z. Chen, « Acute
Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure »,
140:
75:. His thesis and post-doctoral work in this laboratory enabled him to make significant contributions to the understanding of
84:
384:
156:
379:
350:
de The, H. and Z. Chen, « Acute promyelocytic leukaemia: novel insights into the mechanisms of cure »,
152:
71:
in 1984, he chose the medical research internship programme, which he did in Pierre
Tiollais' laboratory at the
96:
404:
394:
80:
374:
27:
23:
180:
131:
Hugues de Thé has received numerous national and international awards: the Mandé Prize From the
34:(2014), member of the French Academy of sciences since 2011. His work, at the interface between
91:
in 1991, he devoted the rest of his career to understanding the leukemogenic function of this
72:
160:
108:
368:
76:
120:
92:
116:
43:
39:
31:
95:. After being recruited as a professor and hospital practitioner at the
112:
35:
26:
and researcher. He is currently a hospital doctor and professor at the
88:
64:
56:
46:, which has become the paradigm for targeted cancer treatments.
67:. Successful for the competitive examination as a resident at
295:
de The, H., « Differentiation therapy revisited »,
42:, has radically transformed the management of a rare form of
390:
French
National Centre for Scientific Research scientists
83:, he then explored the basis of the clinical response of
151:(2004) and has obtained two Advanced Grants from the
22:(born January 18, 1959, in Marseille), is a French
30:, holder of the chair of cellular and molecular
8:
400:Members of the French Academy of Sciences
410:Academic staff of the Collège de France
172:
69:Assistance Publique – Hôpitaux de Paris
155:(ERC). He was named Chevalier in the
7:
311:
309:
143:(2016) and the Sjoberg Prize of the
137:Fondation pour la Recherche Médicale
14:
145:Royal Swedish Academy of Sciences
141:American Society of Hematology
85:acute promyelocytic leukaemias
1:
135:(1996), Rosen Prize from the
99:, he was appointed head of a
50:Biography and scientific work
426:
147:(2018). He is a member of
133:French Academy of Medecine
153:European Research Council
157:Ordre national du Mérite
195:"Académie des sciences"
159:(2001) and then in the
352:Nature reviews. Cancer
97:University of Paris 7
246:, 1990. 347(6293),
211:, 1987. 330(6149),
181:"Collège de France"
385:Cancer researchers
380:French biologists
73:Pasteur Institute
28:Collège de France
417:
359:
357:
354:, 2010. 10(11),
348:
342:
340:
330:
324:
322:
313:
304:
302:
293:
287:
285:
275:
269:
267:
257:
251:
249:
239:
233:
231:
222:
216:
214:
205:
199:
198:
191:
185:
184:
177:
161:Légion d'Honneur
16:French biologist
425:
424:
420:
419:
418:
416:
415:
414:
365:
364:
363:
362:
355:
349:
345:
338:
331:
327:
320:
319:, 2017. 32(5),
314:
307:
300:
299:, 2018. 18(2),
294:
290:
283:
282:, 1991. 66(4),
276:
272:
265:
258:
254:
247:
240:
236:
229:
223:
219:
212:
206:
202:
193:
192:
188:
179:
178:
174:
169:
129:
109:gene expression
61:Necker Hospital
52:
17:
12:
11:
5:
423:
421:
413:
412:
407:
402:
397:
392:
387:
382:
377:
367:
366:
361:
360:
343:
325:
305:
297:Nat Rev Cancer
288:
270:
264:, avril 1990,
252:
234:
217:
200:
186:
171:
170:
168:
165:
128:
125:
59:, then at the
51:
48:
15:
13:
10:
9:
6:
4:
3:
2:
422:
411:
408:
406:
405:Living people
403:
401:
398:
396:
395:Inserm people
393:
391:
388:
386:
383:
381:
378:
376:
373:
372:
370:
353:
347:
344:
337:, 1999. 189,
336:
329:
326:
318:
312:
310:
306:
298:
292:
289:
281:
274:
271:
263:
256:
253:
245:
238:
235:
228:, 1990. 343,
227:
221:
218:
210:
204:
201:
196:
190:
187:
182:
176:
173:
166:
164:
162:
158:
154:
150:
146:
142:
138:
134:
126:
124:
122:
118:
114:
110:
105:
102:
98:
94:
90:
86:
82:
78:
77:retinoic acid
74:
70:
66:
62:
58:
49:
47:
45:
41:
37:
33:
29:
25:
21:
20:Hugues de Thé
351:
346:
335:J. Exp. Med.
334:
328:
316:
296:
291:
279:
273:
261:
255:
243:
237:
225:
220:
208:
203:
189:
175:
130:
127:Distinctions
121:chemotherapy
106:
53:
19:
18:
375:1959 births
317:Cancer Cell
93:oncoprotein
81:Anne Dejean
369:Categories
167:References
117:proteasome
341:1043-1052
44:leukaemia
262:Leukemia
163:(2010).
40:medicine
32:oncology
323:552-560
303:117-127
268:802-807
232:177-180
113:arsenic
36:biology
358:775-83
286:675-84
250:558-61
244:Nature
226:Nature
215:667-70
209:Nature
89:Inserm
24:doctor
65:Paris
280:Cell
149:EMBO
101:CNRS
57:Lyon
38:and
63:in
371::
356:p.
339:p.
321:p.
308:^
301:p.
284:p.
266:p.
248:p.
230:p.
213:p.
197:.
183:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.